GUFICBIO Intraday Analysis...

GUFICBIO Share Price

Open 115.55 Change Price %
High 115.95 1 Day -1.25 -1.10
Low 112.50 1 Week 4.25 3.92
Close 112.70 1 Month -7.55 -6.28
Volume 50179 1 Year 50.50 81.19
52 Week High 144.35
52 Week Low 60.15
GUFICBIO Important Levels
Resistance 2 115.90
Resistance 1 114.58
Pivot 113.72
Support 1 110.82
Support 2 109.50
NSE INDIA Most Active Stocks
RCOM 25.30 9.52%
JPASSOCIAT 19.50 -2.50%
IDBI 75.90 2.99%
ESL 2.25 -4.26%
ESL 2.25 -4.26%
ESL 2.25 -4.26%
ESL 2.25 -4.26%
PNB 97.60 0.77%
HCC 28.80 -5.57%
HCC 28.80 -5.57%
NSE INDIA Top Gainers Stocks
TVTODAY 542.35 15.58%
RAJRAYON 0.40 14.29%
KIOCL 229.90 14.07%
VASWANI 17.15 13.95%
FMNL 125.60 9.98%
PRAXIS 183.05 9.97%
SHYAMTEL 17.90 9.82%
RCOM 25.30 9.52%
BALRAMCHIN 93.55 9.10%
BEDMUTHA 17.25 8.49%
NSE INDIA Top Losers Stocks
INDNIPPON 488.55 -49.46%
BLUECHIP 0.10 -33.33%
VISESHINFO 0.15 -25.00%
SUMEETINDS 23.40 -10.34%
EMCO 10.75 -9.66%
BPL 77.30 -6.47%
BPL 77.30 -6.47%
BPL 77.30 -6.47%
DIAPOWER 10.20 -6.42%
GAMMNINFRA 2.45 -5.77%

Gufic Biosciences Limited (NSE: GUFICBIO)

GUFICBIO Technical Analysis 2
As on 21st Mar 2018 GUFICBIO Share Price closed @ 112.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 89.29 & Strong Sell for SHORT-TERM with Stoploss of 121.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
GUFICBIO Target for March
1st Target up-side 141.6
2nd Target up-side 157.76
3rd Target up-side 173.92
1st Target down-side 95.5
2nd Target down-side 79.34
3rd Target down-side 63.18
GUFICBIO Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 44.93 Sideways
MFI (14) MFI is 53.34 Sideways
CCI (20) CCI is -31.49 Sideways
WILLIAM %R (14) William %R is -53.70 Sideways
ADX (14) ADX is 17.40 Range Bound
PSAR Stoploss For Long Buy 105.69
10 Day Avg Volume Traded -51.30 % Less then 10 Day Average Volume
GUFICBIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
Kamala Bhavan II
Shop - 37, First Floor
Mumbai, 400069
GUFICBIO Latest News
Limited Review for Dec 31, 2014   Hindu Business Line   - 03rd Mar 15
Proposed Bank Strikes   Hindu Business Line   - 17th Feb 15
Gufic Bio standalone Dec '14 sales at Rs 34.34 crore   - 17th Feb 15
BSE Breaches 25.8k Mark; Metals, Goods, Auto and Power Stocks Fall   International Business Times, India Edition   - 04th Jul 14
NPPA sends notices in 89 cases of overcharging to recover   - 22nd Apr 14
Gufic BioSciences Ltd Recommends Dividend   Reuters Key Development   - 31st May 13
Cops hunt for fake drug maker   Times of India   - 24th Feb 09
Interactive Technical Analysis Chart Gufic Biosciences Limited ( GUFICBIO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Gufic Biosciences Limited
GUFICBIO Business Profile
Gufic Biosciences (GUFICBIO) is a pharmaceuticals and biosciences company. Incorporated in 1984 as Central Finance, the company got its current name on Jun. 05, 2000. The company operates in the segments of pharma, healthcare, bio-technology, seeds, herbal, R&D, and bulk drugs. The company provides pharma medicines for diarrhoea (Ridol), episiotomy (Zad-g), anemia (Optifer), infections (Lotril), inflammation (Valsafe)...etc. The healthcare segment provides consumer and personal hygiene products like roll-ons for cold and sanitary napkins like Shapers. The biotechnology segment produces high-yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The tissue culture facility produces five million plants per annum. The company has two green houses of 800 sq. m. Production includes banana, potato, sugarcane, date palm, jatropha, and bixa (source of natural food color). It brings out hybrid varieties of major vegetable seeds like tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. The company provides herbal and ayurvedic medicines for muscular pains (Sallaki); menstrual excesses (Eugynin); hyperacidity, gastritis, and chronic fungal dyspepsia (Zulcer), aches and pains (Rumastal-forte), liver problems (Livpar), constipation (Laxive), and cough (Kofend Syrup). Bulk drugs include anesthetics (lidocaine), antifungals (econazole, miconazole, ketokonazole), antiielmintic (mebendazole, polymorph), cathartic (castor oil), and food colors. The company has its facilities in Vile Parle, Mumbai and a plant in Navsari, Gujarat. The R&D Centre is a state-of-the-art research laboratory and provides total product development by developing new pharmaceutical products, new drug delivery systems, and new platform technologies. The functional areas are formulation development, analytical development, packaging development and documentation. The current market capitalization stands at Rs 44.48 crore. The company has reported a standalone sales of Rs 29.03 crore and a Net Profit of Rs 1.15 crore for the quarter ended September 2013. The company management includes Jayesh P Choksi - Chairman & Managing Director, Pranav J Choksi - Executive & Wholetime Director, M G Dhapalapur - Executive & Wholetime Director, Sharat S Gandhi - Ind. Non-Executive Director, Ashok M Tarale - Ind. Non-Executive Director, Khantilal N Sanghavi - Ind. Non-Executive Director, Pankaj J Gandhi - Additional Director, Jagdish D Shah - Additional Director. The Registered office is at Shop - 37, First Floor, Kamala Bhavan II, Swami Nityanand Road, Mumbai, Maharashtra - 400069.